Shopping Cart 0
Cart Subtotal
AED 0

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 12845

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 25690

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 38535

Details

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Pipeline Review, H2 2017

Summary

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report C-C Chemokine Receptor Type 5-Pipeline Review, H2 2017, outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Immunology, Oncology, Genito Urinary System And Sex Hormones, Metabolic Disorders and Musculoskeletal Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Non-Alcoholic Steatohepatitis (NASH), Graft Versus Host Disease (GVHD), Autoimmune Disorders, Diabetic Nephropathy, Fibrosis, Kidney Fibrosis, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non Alcoholic Fatty Liver Disease (NAFLD), Peritonitis, Pre-Diabetes/Impaired Glucose Tolerance, Primary Sclerosing Cholangitis and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)

The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects

The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Overview 7

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 14

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Therapeutics Assessment 16

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Companies Involved in Therapeutics Development 22

Allergan Plc 22

American Gene Technologies International Inc 23

Bristol-Myers Squibb Company 23

ChemoCentryx Inc 24

Cytodyn Inc 24

GlaxoSmithKline Plc 25

Pharis Biotec GmbH 25

TaiwanJ Pharmaceuticals Co Ltd 26

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Drug Profiles 27

(cenicriviroc mesylate + efavirenz + lamivudine)-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

(cenicriviroc mesylate + evogliptin)-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

(cenicriviroc mesylate + lamivudine)-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

AG-1105-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

BMS-813160-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

CCL-14-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

cenicriviroc mesylate-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

DS-001-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

DS-004-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

DS-005-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

GSK-214096-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

PRO-140-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecule to Antagonize CCR2 and CCR5 for Non-Alcoholic Steatohepatitis-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules to Antagonize CCR1,4,5,6 and CXCR2,7 for Oncology and Autoimmune Disease-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Dormant Products 60

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Discontinued Products 62

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Product Development Milestones 63

Featured News & Press Releases 63

Jun 01, 2017: CytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017 63

May 17, 2017: CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease 63

May 01, 2017: Allergan Announces Presentation on Cenicriviroc at Digestive Disease Week 2017 64

Apr 17, 2017: Potential for CytoDyn's PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA 64

Apr 11, 2017: CytoDyn Appoints Scott A. Kelly, M.D. to Its Board of Directors 64

Feb 15, 2017: CMC Biologics Enters into Manufacturing Agreement with CytoDyn 65

Feb 14, 2017: Two-Year Update From CytoDyn's PRO 140 Monotherapy Study in HIV to be Featured in Two Events at CROI 2017 65

Jan 30, 2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 66

Jan 11, 2017: CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy 66

Dec 12, 2016: CytoDyn Reports Treatment of First Several Patients With PRO 140 in Its Phase 3 Monotherapy Trial for HIV 67

Nov 16, 2016: CytoDyn Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017 67

Nov 11, 2016: Allergan Shows Strong Presence at the AASLD Liver Meeting with Data in Poster Sessions and an Oral Plenary Presentation 68

Oct 24, 2016: CytoDyn Files Protocol for Extended Access to PRO 140 for Patients Who Reach the End of PRO 140 Pivotal Phase 3 Trial 68

Oct 20, 2016: Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting 69

Oct 13, 2016: bioMONTR Labs to Provide Testing Services for CytoDyn PRO 140 Clinical Trials 70

Appendix 71

Methodology 71

Coverage 71

Secondary Research 71

Primary Research 71

Expert Panel Validation 71

Contact Us 71

Disclaimer 72


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 16

Number of Products by Stage and Mechanism of Actions, H2 2017 16

Number of Products by Routes of Administration, H2 2017 18

Number of Products by Stage and Routes of Administration, H2 2017 18

Number of Products by Molecule Types, H2 2017 20

Number of Products by Stage and Molecule Types, H2 2017 20


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13

Number of Products under Investigation by Universities/Institutes, H2 2017 14

Products under Investigation by Universities/Institutes, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Stage and Route of Administration, H2 2017 19

Number of Products by Stage and Molecule Type, H2 2017 21

Pipeline by Allergan Plc, H2 2017 22

Pipeline by American Gene Technologies International Inc, H2 2017 23

Pipeline by Bristol-Myers Squibb Company, H2 2017 23

Pipeline by ChemoCentryx Inc, H2 2017 24

Pipeline by Cytodyn Inc, H2 2017 24

Pipeline by GlaxoSmithKline Plc, H2 2017 25

Pipeline by Pharis Biotec GmbH, H2 2017 25

Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017 26

Dormant Products, H2 2017 60

Dormant Products, H2 2017 (Contd..1), H2 2017 61

Discontinued Products, H2 2017 62

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Therapeutic Products under Development, Key Players in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Therapeutics, C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Pipeline Overview, C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Pipeline, C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Pipeline Assessment


Companies

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Therapeutic Products under Development, Key Players in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Therapeutics, C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Pipeline Overview, C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Pipeline, C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Pipeline Assessment

Company Profile

Company Profile Title

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Pipeline Review, H2 2017

Summary

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report C-C Chemokine Receptor Type 5-Pipeline Review, H2 2017, outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Immunology, Oncology, Genito Urinary System And Sex Hormones, Metabolic Disorders and Musculoskeletal Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Non-Alcoholic Steatohepatitis (NASH), Graft Versus Host Disease (GVHD), Autoimmune Disorders, Diabetic Nephropathy, Fibrosis, Kidney Fibrosis, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non Alcoholic Fatty Liver Disease (NAFLD), Peritonitis, Pre-Diabetes/Impaired Glucose Tolerance, Primary Sclerosing Cholangitis and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)

The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects

The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Overview 7

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 14

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Therapeutics Assessment 16

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Companies Involved in Therapeutics Development 22

Allergan Plc 22

American Gene Technologies International Inc 23

Bristol-Myers Squibb Company 23

ChemoCentryx Inc 24

Cytodyn Inc 24

GlaxoSmithKline Plc 25

Pharis Biotec GmbH 25

TaiwanJ Pharmaceuticals Co Ltd 26

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Drug Profiles 27

(cenicriviroc mesylate + efavirenz + lamivudine)-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

(cenicriviroc mesylate + evogliptin)-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

(cenicriviroc mesylate + lamivudine)-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

AG-1105-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

BMS-813160-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

CCL-14-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

cenicriviroc mesylate-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

DS-001-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

DS-004-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

DS-005-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

GSK-214096-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

PRO-140-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecule to Antagonize CCR2 and CCR5 for Non-Alcoholic Steatohepatitis-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules to Antagonize CCR1,4,5,6 and CXCR2,7 for Oncology and Autoimmune Disease-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Dormant Products 60

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Discontinued Products 62

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)-Product Development Milestones 63

Featured News & Press Releases 63

Jun 01, 2017: CytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017 63

May 17, 2017: CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease 63

May 01, 2017: Allergan Announces Presentation on Cenicriviroc at Digestive Disease Week 2017 64

Apr 17, 2017: Potential for CytoDyn's PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA 64

Apr 11, 2017: CytoDyn Appoints Scott A. Kelly, M.D. to Its Board of Directors 64

Feb 15, 2017: CMC Biologics Enters into Manufacturing Agreement with CytoDyn 65

Feb 14, 2017: Two-Year Update From CytoDyn's PRO 140 Monotherapy Study in HIV to be Featured in Two Events at CROI 2017 65

Jan 30, 2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 66

Jan 11, 2017: CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy 66

Dec 12, 2016: CytoDyn Reports Treatment of First Several Patients With PRO 140 in Its Phase 3 Monotherapy Trial for HIV 67

Nov 16, 2016: CytoDyn Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017 67

Nov 11, 2016: Allergan Shows Strong Presence at the AASLD Liver Meeting with Data in Poster Sessions and an Oral Plenary Presentation 68

Oct 24, 2016: CytoDyn Files Protocol for Extended Access to PRO 140 for Patients Who Reach the End of PRO 140 Pivotal Phase 3 Trial 68

Oct 20, 2016: Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting 69

Oct 13, 2016: bioMONTR Labs to Provide Testing Services for CytoDyn PRO 140 Clinical Trials 70

Appendix 71

Methodology 71

Coverage 71

Secondary Research 71

Primary Research 71

Expert Panel Validation 71

Contact Us 71

Disclaimer 72


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 16

Number of Products by Stage and Mechanism of Actions, H2 2017 16

Number of Products by Routes of Administration, H2 2017 18

Number of Products by Stage and Routes of Administration, H2 2017 18

Number of Products by Molecule Types, H2 2017 20

Number of Products by Stage and Molecule Types, H2 2017 20


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13

Number of Products under Investigation by Universities/Institutes, H2 2017 14

Products under Investigation by Universities/Institutes, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Stage and Route of Administration, H2 2017 19

Number of Products by Stage and Molecule Type, H2 2017 21

Pipeline by Allergan Plc, H2 2017 22

Pipeline by American Gene Technologies International Inc, H2 2017 23

Pipeline by Bristol-Myers Squibb Company, H2 2017 23

Pipeline by ChemoCentryx Inc, H2 2017 24

Pipeline by Cytodyn Inc, H2 2017 24

Pipeline by GlaxoSmithKline Plc, H2 2017 25

Pipeline by Pharis Biotec GmbH, H2 2017 25

Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017 26

Dormant Products, H2 2017 60

Dormant Products, H2 2017 (Contd..1), H2 2017 61

Discontinued Products, H2 2017 62

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Therapeutic Products under Development, Key Players in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Therapeutics, C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Pipeline Overview, C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Pipeline, C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Pipeline Assessment


Companies

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Therapeutic Products under Development, Key Players in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Therapeutics, C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Pipeline Overview, C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Pipeline, C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Pipeline Assessment